Molecular Partners (NASDAQ:MOLN) Upgraded to Strong-Buy by Leerink Partnrs

Molecular Partners (NASDAQ:MOLN) was upgraded by research analysts at Leerink Partnrs to a “strong-buy” rating in a research note issued to investors on Monday, Zacks.com reports.

Molecular Partners Price Performance

Shares of MOLN stock opened at $4.76 on Monday. The firm has a market cap of $174.61 million, a P/E ratio of -2.36 and a beta of 0.99. Molecular Partners has a 1-year low of $3.32 and a 1-year high of $12.70. The firm has a fifty day moving average of $5.82 and a two-hundred day moving average of $5.28.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings data on Monday, August 26th. The company reported ($0.51) EPS for the quarter. The business had revenue of $1.72 million during the quarter. Molecular Partners had a negative return on equity of 33.15% and a negative net margin of 730.27%. On average, sell-side analysts expect that Molecular Partners will post -2.03 EPS for the current year.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.